Robert Dee Etherington

Vorstandsvorsitzender bei CLENE INC.

Vermögen: 32 726 $ am 30.04.2024

57 Jahre

Health Technology

Consumer Services

Aktive Positionen von Robert Dee Etherington

Unternehmen	Position	Beginn	Ende
CLENE INC.	Direktor/Vorstandsmitglied	01.01.2020	-
	Vorstandsvorsitzender	01.04.2013	-
	Präsident	01.04.2013	-
BioUtah	Direktor/Vorstandsmitglied	01.06.2016	-
Clene Nanomedicine, Inc. Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.	Direktor/Vorstandsmitglied	-	-
	Vorstandsvorsitzender	01.04.2013	-
	Präsident	01.04.2013	-
Corsair LLC	Direktor/Vorstandsmitglied	01.03.2018	-

Unternehmen	Position	Beginn	Ende
Actelion Pharmaceuticals Ltd. Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The company is based in Allschwil, Switzerland.	Vertrieb & Marketing	01.09.2000	01.03.2013

Brigham Young University

Masters Business Admin

International

Vereinigte Staaten	6
Schweiz	2

Operativ

Sektoral

Health Technology	4
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
CLENE INC.	Health Technology

Private Unternehmen	4
BioUtah
Clene Nanomedicine, Inc. Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.	Health Technology
Actelion Pharmaceuticals Ltd. Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals Ltd. is a Swiss company that develops and distributes molecular weight drugs. The company is based in Allschwil, Switzerland.	Health Technology
Corsair LLC